Dominik M Wiktor1, John D Carroll2. 1. University of Colorado, Anschutz Medical Campus, Mail Stop B132, Leprino Office Building, 12401 East 17th Avenue, Room 524, Aurora, CO, 80045, USA. dominik.wiktor@ucdenver.edu. 2. University of Colorado, Anschutz Medical Campus, Mail Stop B132, Leprino Office Building, 12401 East 17th Avenue, Room 524, Aurora, CO, 80045, USA.
Abstract
PURPOSE OF REVIEW: While the safety and efficacy of percutaneous ASD closure has been established, new data have recently emerged regarding the negative impact of residual iatrogenic ASD (iASD) following left heart structural interventions. Additionally, new devices with potential advantages have recently been studied. We will review here the potential indications for closure of iASD along with new generation closure devices and potential late complications requiring long-term follow-up. RECENT FINDINGS: With the expansion of left-heart structural interventions and large-bore transseptal access, there has been growing experience gained with management of residual iASD. Some recently published reports have implicated residual iASD after these procedures as a potential source of diminished clinical outcomes and mortality. Additionally, recent trials investigating new generation closure devices as well as expanding knowledge regarding late complications of percutaneous ASD closure have been published. While percutaneous ASD closure is no longer a novel approach to managing septal defects, there are several contemporary issues related to residual iASD following large-bore transseptal access and new generation devices which serve as an impetus for this review. Ongoing attention to potential late complications and decreasing their incidence with ongoing study is clearly needed.
PURPOSE OF REVIEW: While the safety and efficacy of percutaneous ASD closure has been established, new data have recently emerged regarding the negative impact of residual iatrogenic ASD (iASD) following left heart structural interventions. Additionally, new devices with potential advantages have recently been studied. We will review here the potential indications for closure of iASD along with new generation closure devices and potential late complications requiring long-term follow-up. RECENT FINDINGS: With the expansion of left-heart structural interventions and large-bore transseptal access, there has been growing experience gained with management of residual iASD. Some recently published reports have implicated residual iASD after these procedures as a potential source of diminished clinical outcomes and mortality. Additionally, recent trials investigating new generation closure devices as well as expanding knowledge regarding late complications of percutaneous ASD closure have been published. While percutaneous ASD closure is no longer a novel approach to managing septal defects, there are several contemporary issues related to residual iASD following large-bore transseptal access and new generation devices which serve as an impetus for this review. Ongoing attention to potential late complications and decreasing their incidence with ongoing study is clearly needed.
Authors: John Moore; Sanjeet Hegde; Howaida El-Said; Robert Beekman; Lee Benson; Lisa Bergersen; Ralf Holzer; Kathy Jenkins; Richard Ringel; Jonathan Rome; Robert Vincent; Gerard Martin Journal: JACC Cardiovasc Interv Date: 2013-05 Impact factor: 11.195
Authors: Carole A Warnes; Roberta G Williams; Thomas M Bashore; John S Child; Heidi M Connolly; Joseph A Dearani; Pedro Del Nido; James W Fasules; Thomas P Graham; Ziyad M Hijazi; Sharon A Hunt; Mary Etta King; Michael J Landzberg; Pamela D Miner; Martha J Radford; Edward P Walsh; Gary D Webb Journal: J Am Coll Cardiol Date: 2008-12-02 Impact factor: 24.094
Authors: Walter Wilson; Kathryn A Taubert; Michael Gewitz; Peter B Lockhart; Larry M Baddour; Matthew Levison; Ann Bolger; Christopher H Cabell; Masato Takahashi; Robert S Baltimore; Jane W Newburger; Brian L Strom; Lloyd Y Tani; Michael Gerber; Robert O Bonow; Thomas Pallasch; Stanford T Shulman; Anne H Rowley; Jane C Burns; Patricia Ferrieri; Timothy Gardner; David Goff; David T Durack Journal: Circulation Date: 2007-04-19 Impact factor: 29.690
Authors: John D Carroll; Jeffrey L Saver; David E Thaler; Richard W Smalling; Scott Berry; Lee A MacDonald; David S Marks; David L Tirschwell Journal: N Engl J Med Date: 2013-03-21 Impact factor: 91.245
Authors: Joshua A Vecht; Srdjan Saso; Christopher Rao; Konstantinos Dimopoulos; Julia Grapsa; Cesare M Terracciano; Nicholas S Peters; Petros Nihoyannopoulos; Elaine Holmes; Michael A Gatzoulis; Thanos Athanasiou Journal: Heart Date: 2010-11 Impact factor: 5.994
Authors: Alvaro Aparisi; Roman J Arnold; Hipólito Gutiérrez; Ana Revilla; Ana Serrador; Benigno Ramos; Tania Rodriguez-Gabella; Alberto Campo; Carlos Baladrón; Itziar Gómez; Manuel Carrasco-Moraleja; José A San Roman; Ignacio J Amat-Santos Journal: Cardiol J Date: 2020-04-24 Impact factor: 2.737
Authors: Ho Xuan Tuan; Phan The Phuoc Long; Vu Duy Kien; Le Manh Cuong; Nguyen Van Son; Robert Dalla-Pozza Journal: J Cardiovasc Dev Dis Date: 2019-12-27